Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
NCT ID: NCT05040373
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10 participants
OBSERVATIONAL
2020-08-01
2030-10-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patisiran
Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Alnylam Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Nantes, , France
Clinical Trial Site
Münster, , Germany
Clinical Trial Site
Pavia, , Italy
Clinical Trial Site
Groningen, , Netherlands
Clinical Trial Site
Lisbon, , Portugal
Clinical Trial Site
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Alnylam Clinical Trial Information Line
Role: CONTACT
Phone: 1-877-256-9526
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-TTR02-010
Identifier Type: -
Identifier Source: org_study_id